Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Is there a standard of care for relapsed AML?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Bruno C. MedeirosAbstractDespite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival for patients with relapsed AML ranges from 4-6 months and long-term survival from the time of relapse ranges from 5%-20%. Much of the difficulty in establishing a standard of care for relapsed AML is that the disease is clinically and genomically diverse. Nevertheless, significant progress has been made over the past 12 months ...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes
This article reviews the rationale for hypomethylating agents, their use or intensive chemotherapy pre-transplant, and data supporting pre-transplant MDS treatment. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Progress and predictions: AML in 2018
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Jacob M. RoweAbstractThe FLT3 inhibitor midostaurin, the antibody-drug conjugate gemtuzumab ozogamicin, CPX-351 (liposomal daunorubicin and cytarabine), and the IDH2 inhibitor enasidenib are among the novel agents approved for use in the clinic this past year. This year, 2018, already has seen the regulatory approval of the BCL2 inhibitor venetoclax in the form of breakthrough designation and the IDH1 inhibitor ivosidenib received full FDA approval. Much remains to be learned about how best to use these drugs...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Frederick R. AppelbaumThe persistence of measurable residual disease (MRD) following induction chemotherapy is the single most powerful prognostic factor available to clinicians treating patients with acute myeloid leukemia (AML). How to use this information to guide subsequent therapy is complex, and influenced by the category of AML being treated, the assays used to measure MRD, MRD levels and kinetics, and the spectrum of therapies available to the patient. In this literature-based review, each of these is...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Allogeneic transplantation among patients with Ph+ ALL: Is it imperative in the TKI era?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Mark R. LitzowAbstractBefore the advent of tyrosine kinase inhibitors (TKIs), Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Is the overall survival for older adults with AML finally improving?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Jeffrey E. LancetAbstractOlder adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall survival than those who undergo treatment, regardless of treatment type, and improvements in overall survival in the last several decades are largely attributable to the increasing decision to treat rather than offer only supportive care. However, there are a few newer agents that appear promising; these include CPX-351 (a liposomal p...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Why and how to treat Ph-like ALL?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Kathryn G. RobertsAbstractPhiladelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), or BCR-ABL1-like ALL, is a high-risk subtype of B-cell precursor ALL characterized by a gene expression profile similar to Ph-positive ALL, a high frequency of IKZF1 alterations, and poor outcome. The prevalence of Ph-like ALL is common among all ages, ranging from 10%-15% in children to over 25% in young adults. Patients with Ph-like ALL harbor a diverse range of genetic alterations that activate cytokine recep...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Which novel agents for acute myeloid leukemia are likely to change practice?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Danial A. PollyeaAbstractThere has been little progress in drug development in acute myeloid leukemia (AML) in the recent past. This recently changed with the approval of several therapies for patients with this disease and prompts one to consider which therapies may change practice for patients with AML. To change practice, a therapy must be adopted as a standard of care intervention based on its efficacy and safety profile and must endure as the accepted treatment for a particular indication for a significa...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: September 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 3Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - September 11, 2018 Category: Hematology Source Type: research

Index
Publication date: September 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 3Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - September 11, 2018 Category: Hematology Source Type: research

Editor's introduction
Publication date: Available online 15 August 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Laurie H. Sehn (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - August 15, 2018 Category: Hematology Source Type: research

Optimizing initial therapy in DLBCL
Publication date: Available online 7 August 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Catherine Thieblemont, Sophie Bernard, Michel Meignan, Thierry MolinaAbstractDiffuse large B-cell lymphoma (DLBCL) is a group of lymphomas comprising heterogeneous molecular and biological subtypes, reflected in a broad range of clinical outcomes. With the standard R-CHOP regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab administered every 21 days, the treatment failure rate remains unacceptably high in certain DLBCL subsets. Here we review possible avenues for optimizing initia...
Source: Best Practice and Research Clinical Haematology - August 7, 2018 Category: Hematology Source Type: research

The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Publication date: Available online 1 August 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Ranjit Nair, Sattva S. NeelapuAbstractRelapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the United States Food and Drug Administration for the treatment of relapsed or refractory large B-cell ...
Source: Best Practice and Research Clinical Haematology - August 1, 2018 Category: Hematology Source Type: research

Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome
Publication date: Available online 18 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): H. Miles Prince, Christiane QuerfeldAbstractNovel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab vedotin and mogamulizumab. Extracorporeal photopheresis is particularly eff...
Source: Best Practice and Research Clinical Haematology - July 26, 2018 Category: Hematology Source Type: research

Double Hit Lymphoma: How do we define it and how do we treat it?
Publication date: Available online 26 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Brídgín Merron, Andrew DaviesAbstractDouble/triple hit lymphoma is recognised as a distinct entity within the heterogeneous group of high grade B-cell lymphomas, accounting for between 5-10% of cases of diffuse large B-cell lymphoma,. Under the WHO 2016 it is now known as high-grade B-cell lymphoma with rearrangements of MYC and/or BCL2 and BCL6. When treated with standard chemotherapy it has a poor outcome. There is currently no standard of care for the management of this condition.Diagnosing double hit lymphom...
Source: Best Practice and Research Clinical Haematology - July 26, 2018 Category: Hematology Source Type: research